Anupam Rasayan India, one of leading custom synthesis and specialty chemical players, opened fiscal 2027 on a strong footing, reporting a 36% year-on-year jump in consolidated revenue for the quarter ended June 30, 2026.

 

The company reported consolidated revenue of Rs. 667.5 crore in Q1FY27, up from Rs. 490.7 crore a year earlier. EBITDA climbed to Rs. 174.9 crore from Rs. 129.2 crore, while PAT stood at Rs. 51.2 crore.

 

Profit after tax increased 6% to Rs. 51.2 crore, compared with Rs. 48.5 crore in Q1FY26.

 

The performance comes as Anupam Rasayan advances its strategy of building a globally integrated specialty chemicals and CDMO platform, with new technology milestones and potential long-term customer opportunities adding to its growth pipeline.

 

Anand Desai, Managing Director, Anupam Rasayan India Limited, said, "We are pleased to begin fiscal year 2027 on a strong note. Consolidated Revenue for the quarter grew 36% year-on-year, a result that reflects sustained momentum across our businesses and continued execution of our strategy to build a globally integrated specialty chemicals and CDMO platform.

 

"We would like to highlight an important technological milestone achieved during the quarter. We became the first company in the world to commercialize Ethyl Trifluoroacetate, or ETFA, using flow chemistry - a significant advancement that further strengthens our capabilities in complex fluorination.

 

"We also signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product. This represents a revenue opportunity of approximately US$300 million spread over a period of ten years."

 

He added: "Turning to our pharmaceutical business, the proposed acquisition of Bliss GVS Pharma continues to progress as planned, following the signing of the definitive agreement. Upon completion, we expect this transaction to strengthen our pharmaceutical platform through synergies across CDMO capabilities, product development, customer relationships, and access to regulated markets.

 

"Looking ahead, we remain confident in our growth prospects. This confidence is supported by a strong product pipeline, expanding opportunities across our Performance Materials and Pharmaceuticals segments, deeper customer engagement, and continued investment in technology and innovation. Together, these initiatives position us well to deliver sustainable growth and long-term value creation."

 

The company said its growth outlook remains supported by its product pipeline, expanding opportunities in Performance Materials and Pharmaceuticals, deeper customer engagement and continued investment in technology and innovation.